Table 1.
Demographics and baseline characteristics (FAS)
| Characteristics | Placebo | Bimekizumab (mg) | |||||
| n=14 | 80/40/40 n=6 |
160/80/80 n=6 |
240/160/160 n=20 |
560/320/320 n=6 |
Three top doses n=32 |
All patients n=52 |
|
| Mean age (years) | 37.4 | 46.5 | 40.0 | 48.5 | 43.5 | 45.9 | 43.7 |
| Gender, n (%) Male |
9 (64.3) | 3 (50.0) | 1 (16.7) | 9 (45.0) | 4 (66.7) | 14 (43.8) | 26 (50.0) |
| Duration of PsA (years) Mean (range) |
5.3 (0.5–25.1) | 6.1 (2.2–15.2) | 5.9 (2.2–11.1) | 8.0 (0.6–26.6) | 6.2 (0.2–15.6) | 7.3 (0.2–26.6) | 6.6 (0.2–26.6) |
| Prior/concomitant use of TNF inhibitors (n) | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
| SJC (66) Mean (SD) |
13.4 (11.6) | 11.9 (11.9) | 10.3 (6.8) | 12.6 (7.4) | 14.0 (12.7) | 12.5 (8.3) | 12.6 (9.5) |
| TJC (68) Mean (SD) |
33.4 (20.1) | 22.2 (20.7) | 30.0 (26.2) | 31.7 (19.1) | 20.5 (22.9) | 29.3 (20.9) | 29.6 (20.5) |
| CRP (mg/L) Mean (SD) |
13.8 (24.6) | 20.8 (44.3) | 3.7 (3.6) | 14.3 (22.5) | 5.8 (5.4) | 10.7 (18.4) | 12.5 (23.1) |
| LEI Mean (SD) |
3.8 (2.6) | 2.7 (1.8) | 2.7 (2.7) | 2.8 (2.3) | 2.7 (2.3) | 2.8 (2.3) | 3.0 (2.3) |
| 23 patients with skin involvement of >3% body surface area | |||||||
| Patients with body surface area ≥3% psoriasis (%) | 6 (43) | 2 (33) | 4 (67) | 9 (45) | 2 (33) | 15 (47) | 23 (44) |
| PASI Mean (SD) |
18.5 (16.3) | Not calculated | 4.7 (3.3) | 15.2 (9.8) | Not calculated | 11.1 (9.2) | 15.9 (14.6) |
CRP, C reactive protein; FAS, full analysis set; LEI, Leeds Enthesitis Index; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; SJC, swollen joint count; TJC, tender joint count; TNF, tumour necrosis factor.